MA40536A - Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations - Google Patents

Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations

Info

Publication number
MA40536A
MA40536A MA040536A MA40536A MA40536A MA 40536 A MA40536 A MA 40536A MA 040536 A MA040536 A MA 040536A MA 40536 A MA40536 A MA 40536A MA 40536 A MA40536 A MA 40536A
Authority
MA
Morocco
Prior art keywords
antibodies
beta
alpha
humanized anti
disclosed
Prior art date
Application number
MA040536A
Other languages
English (en)
Inventor
Thomas Owen Cameron
Michael Adam Crackower
Brian M Dolinski
Karl J M Hanf
Amy Theresa Mccurley
Nels Eric Pederson
Martin Preyer
Fang Qian
Shelia M Violette
Paul Henry Weinreb
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA40536A publication Critical patent/MA40536A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La présente invention concerne des anticorps et des fragments d'anticorps humanisés qui se lient au αvβ5. L'invention concerne également des méthodes d'utilisation de ces anticorps et de ces fragments d'anticorps pour traiter ou prévenir des maladies à médiation par l'αvβ5.
MA040536A 2014-09-12 2015-09-11 Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations MA40536A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049987P 2014-09-12 2014-09-12

Publications (1)

Publication Number Publication Date
MA40536A true MA40536A (fr) 2016-03-17

Family

ID=54150752

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040536A MA40536A (fr) 2014-09-12 2015-09-11 Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations

Country Status (9)

Country Link
US (1) US20170362324A1 (fr)
EP (1) EP3191519A1 (fr)
JP (1) JP2017534252A (fr)
CN (1) CN107001469A (fr)
AU (1) AU2015314809A1 (fr)
CA (1) CA2959772A1 (fr)
MA (1) MA40536A (fr)
MX (1) MX2017003014A (fr)
WO (1) WO2016040839A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481347A (zh) * 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
CA3223687A1 (fr) * 2016-09-29 2018-04-05 The Regents Of The University Of California Anticorps neutralisants diriges contre le complexe d'integrine .alpha.v.beta.8 pour l'immunotherapie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
KR20000016301A (ko) * 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
PT1734996E (pt) * 2004-04-02 2013-07-18 Univ California Métodos e composição para tratamento e prevenção de doenças associadas a integrina αvβ5
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN102481347A (zh) * 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
WO2012027745A1 (fr) * 2010-08-27 2012-03-01 University Of Miami Traitement de maladies rénales
CN105121472A (zh) * 2012-10-30 2015-12-02 埃斯佩兰斯医药公司 抗体/药物缀合物及其使用方法

Also Published As

Publication number Publication date
EP3191519A1 (fr) 2017-07-19
AU2015314809A1 (en) 2017-03-16
JP2017534252A (ja) 2017-11-24
US20170362324A1 (en) 2017-12-21
WO2016040839A1 (fr) 2016-03-17
CN107001469A (zh) 2017-08-01
CA2959772A1 (fr) 2016-03-17
MX2017003014A (es) 2017-05-30

Similar Documents

Publication Publication Date Title
NZ738008A (en) Tigit-binding agents and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12018501177A1 (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
EA201790342A1 (ru) Антитела к trem2 и способы их применения
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
EP4249515A3 (fr) Anticorps anti-cd3 humanisés ou chimériques
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2018003450A (es) Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso.
MX2015011670A (es) Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
PH12017501522B1 (en) Antibodies to tau and uses thereof
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
PH12016501366A1 (en) Novel anti-baff antibodies
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
WO2014143739A3 (fr) Anticorps anti-alpha ν bêta 6 et leurs utilisations
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
WO2014144616A3 (fr) Anticorps anti-alpha ν bêta 5 et leurs utilisations